Advances in Genetics and Cell Biology coupled with high throughput screening (HTS) in the early 1990s led to significant advances in drug discovery. In combination with improved and more efficient drug development procedures, biotechnology led to the production of life saving pharmaceutical products for numerous life threating diseases from hematological malignancies and solid tumors to various genetic and other rare diseases.

 In the coming years further advances in cellular models, the rise of gene editing technologies and AI coupled with significant improvements in data analysis, will lead to a new era of drug discovery and development with an even stronger focus on rare diseases and various immune-oncology targets. 

Based on our mission to serve patients, their families as also their treating physicians in their fight against severe, chronic and rare diseases, we believe that patients in Greece should have access to the most innovative upcoming therapeutic approaches.

Our high-quality standards, strong expertise in market access, sales and marketing of specialty products and rare disease products and our highly experienced and successful Leadership Team and Salesforce, supported by our excellent relationships across all categories of local health sector stakeholders, enable us to be the partner of choice for the Greek market.

We are open to work under different business models including:

Distribution agreements and local representation of international companies

Investing in long-term collaboration with international business partners aiming to expand their portfolio of new biotechnology products to Greece and Cyprus remains for us the primary strategic priority. 

We continuously follow up the international pharmaceutical field for latest information about new treatments, research projects and clinical trials advances in the therapeutic areas of focus and aim to create interest to selected biopharmaceutical companies in order to expand our product portfolio.

Early Access Agreements

We can offer immediate launch and reimbursement of innovative products such as Specialty Products or Rare Diseases Products, through early access programs after EMA approval.

Support of registrational studies in therapeutic areas of interest

For the therapeutic areas of interest for our company we support the participation of Greek Hospitals in Phase III clinical trials with the aim to accelerate access to the new therapy for Greek patients after the product receives EMA approval.